ASX Announcements
Notification of cessation of securities - HLS
Appendix 3H (Notification of cessation of securities)
- Oct 3, 2024
- 5 pages
Market Sensitive
Lumus Imaging Sale Presentation
Company Presentation, Asset Disposal
- Sep 23, 2024
- 8 pages
September
Tanarra Capital says at $835m the price is right for Healius
Shares in the pathology company jumped 7.5 per cent after it achieved a robust price for Lumus, which does MRI, X-rays and CT scans.
- Simon Evans
- Opinion
- Chanticleer
Private equity cash wipes Healius slate clean – just don’t look back
While it’s a shame it got to the point that the company had to sell its radiology arm, and that it took so long to get there, everyone involved can now move on.
- Anthony Macdonald
Affinity Equity Partners buys Healius’ Lumus for $900m-plus
All other bidders, including Pacific Equity Partners, are “pens down”, according to sources close to the Swiss bank.
- Updated
- Sarah Thompson, Kanika Sood and Emma Rapaport
- Exclusive
- Mergers & acquisitions
John Wylie’s Tanarra urges Healius to halt $700m imaging business sale
The country’s second-largest pathology group has been considering selling its Lumus division. But the outspoken investor says it’s going too well to offload.
- Simon Evans
August
- Results Wrap
- Chanticleer
How Scentre came through the Bondi Junction tragedy
Amid a deluge of results, it was a story about something much more than money that moved us here at Chanticleer.
- James Thomson and Anthony Macdonald
Healius’ net loss doubles as it restructures, sells imaging unit
The pathology group says the sale of its imaging business is “well advanced” as it posted a net loss in line with expectations.
- Michael Smith
Race for Healius’ $700m Lumus business down to just three as IFM exits
The company, led by Paul Anderson, has had an embarrassing three years, starting with a poorly priced acquisition of Agilex Biolabs in 2021.
- Sarah Thompson, Kanika Sood and Emma Rapaport
Switzerland’s Unilabs takes a look at $4b I-MED radiology business
The company’s British private equity owners, Permira, brought in Morgan Stanley and Jefferies earlier this year to work on plans for a bumper payday.
- Sarah Thompson, Kanika Sood and Emma Rapaport
July
PE titans lob bids for Healius’ $700m Lumus Imaging; UBS offers staple
Many have taken a look at Healius’ Lumus Imaging, but it was TPG Capital and Affinity Private Equity that put pen to paper when UBS collected offers last week.
- Sarah Thompson, Kanika Sood and Emma Rapaport
June
Radiology’s AI future and deregulation help end years of bad blood
The No.1 player in an industry sets the tone. And in radiology, the tone is deals, deals, deals.
- Anthony Macdonald
Integral Diagnostics dealmaking creates $1b diagnostics giant
The company has proposed a merger with its smaller rival, Capitol Health, creating the largest pure-play diagnostics imaging group on the ASX.
- Kylar Loussikian
- Opinion
- Chanticleer
What Australia’s great contrarian is buying – and avoiding
Soaring household debt will have ripple effects for ASX investors, according to Schroders’ head of Australian equity, Martin Conlon.
- Updated
- James Thomson
Crescent Capital set to take radiology business off The Growth Fund
Crescent Capital, which claims to be the country’s most active private equity manager in healthcare, has secured exclusivity.
- Sarah Thompson, Kanika Sood and Emma Rapaport
May
Healius to sell $650m X-ray and ultrasound division after UBS review
The struggling pathology company told investors it had engaged advisers to sell Lumus Imaging as it focuses on reinvigorating its core pathology business.
- Simon Evans
- Opinion
- Pathology
This routine health test is an investment opportunity
The share prices of pathology companies are below pre-pandemic levels and the world will need more blood tests.
- Mark Draper
Why Rio Tinto is worth more than its $130 price tag
Maple-Brown Abbott’s Emma Pringle is betting the iron ore giant’s share price has more room to run. She’s also bullish on Healius despite a shaky 12 months.
- Joanne Tran
March
Healius in management shake-up after CEO exit
Australia’s No.2 pathology group is cutting costs in a restructure to try to turn around a profit slump, as UBS pushes on with a strategic review.
- Simon Evans
Making excuses for weak margins has ended: Healius CEO
In a closed-door staff briefing, the new boss of the struggling pathology group said the company had not “done a good enough job” of setting up “for success”.
- Simon Evans
Dimon on recession, bubbles and Trump | Dutton backs four-year terms | Lowe’s new gig
Read everything that’s happened in the news so far today.
Healius brings in UBS as it reviews strategy, considers asset sales
The company replaced its chief executive, Maxine Jacquet, earlier this month after just 12 months. It runs some 2000 pathology centres and 100 laboratories.
- Simon Evans